Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Philip M. Spanheimer"'
Autor:
Selena J. An, Emilie D. Duchesneau, Paula D. Strassle, Katherine Reeder-Hayes, Kristalyn K. Gallagher, David W. Ollila, Stephanie M. Downs-Canner, Philip M. Spanheimer
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The role of de-escalated therapy in the neoadjuvant setting, however, remains uncertain. We conducted a coh
Externí odkaz:
https://doaj.org/article/36ce3c13741640788730971908f90c3d
Publikováno v:
The Lancet Oncology. 23:1477-1479
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0138a74d7d554459839024ade6ab7fc6
https://doi.org/10.1016/s1470-2045(22)00649-0
https://doi.org/10.1016/s1470-2045(22)00649-0
Autor:
Maire J. Amlicke, Jihye Park, Chris B. Agala, Dana L. Casey, Emily M. Ray, Stephanie M. Downs-Canner, Philip M. Spanheimer
Publikováno v:
Annals of Surgical Oncology. 29:7662-7669
The RxPONDER trial demonstrated that the 21-gene recurrence score can be used to guide adjuvant systemic therapy decisions in postmenopausal women with pN1 ER+/HER2- breast cancer. As such, a sentinel lymph node biopsy (SLNB) may not provide systemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95f8efa24b44ee888dcffe8dd6b14bd
https://doi.org/10.1245/s10434-022-12056-4
https://doi.org/10.1245/s10434-022-12056-4
Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells
Autor:
Tarek M. Zikry, Samuel C. Wolff, Jolene S. Ranek, Harris Davis, Ander Naugle, Austin A. Whitman, Michael R. Kosorok, Philip M. Spanheimer, Jeremy E. Purvis
The CDK4/6 inhibitor palbociclib blocks cell cycle progression in ER+/HER2- breast tumor cells. Although these drugs have significantly improved patient outcomes in metastatic breast cancers, a small percentage of tumor cells continues to divide in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d303f7359c81fae55b36fa940beacd36
https://doi.org/10.1101/2023.05.22.541831
https://doi.org/10.1101/2023.05.22.541831
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Resistance to endocrine therapy is the primary cause of treatment failure and death in patients with ER-positive (ER+)/luminal breast cancer. Expression and activation of the RET receptor tyrosine kinase may be driving poor outcomes. We aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::723f9de338d246b275884df1261e8993
https://europepmc.org/articles/PMC10182256/
https://europepmc.org/articles/PMC10182256/
Autor:
Ronald J. Weigel, Philip M. Spanheimer, Sarah E. Van Dorin, Vincent T. Wu, Allison W. Lorenzen, Mikhail V. Kulak, George W. Woodfield, Vivian W. Gu, Jung M. Park, James P. De Andrade
Supplemental Figure 1: Knockdown of RET expression with siRNA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b79a4cd90b959d3f48ded9b9b82722f
https://doi.org/10.1158/1535-7163.22504047.v1
https://doi.org/10.1158/1535-7163.22504047.v1
Autor:
Hyunsoo Kim, Austin A. Whitman, Kamila Wisniewska, Rasha T. Kakati, Susana Garcia-Recio, Benjamin C. Calhoun, Hector L. Franco, Charles M. Perou, Philip M. Spanheimer
In ER+/HER2- breast cancer, multiple measures of intra-tumor heterogeneity are associated with worse response to endocrine therapy. To investigate heterogeneity in response to treatment, we developed an operating room-to-laboratory pipeline for the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdd165c03100ad0f8ad55e228c7d69e8
https://doi.org/10.1101/2023.04.01.535159
https://doi.org/10.1101/2023.04.01.535159
Autor:
Ronald J. Weigel, Alexandra Thomas, Sonia L. Sugg, Anthony R. Cyr, James P. De Andrade, George W. Woodfield, Mikhail V. Kulak, Ryan W. Askeland, Jung-Min Park, Philip M. Spanheimer
Purpose: Recent findings suggest that combination treatment with antiestrogen and anti-RET may offer a novel treatment strategy in a subset of patients with breast cancer. We investigated the role of RET in potentiating the effects of antiestrogen re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bbdfdcfd7ad2fc222940f2d60f2375
https://doi.org/10.1158/1078-0432.c.6521372
https://doi.org/10.1158/1078-0432.c.6521372
Autor:
Ronald J. Weigel, Alexandra Thomas, Sonia L. Sugg, Anthony R. Cyr, James P. De Andrade, George W. Woodfield, Mikhail V. Kulak, Ryan W. Askeland, Jung-Min Park, Philip M. Spanheimer
PDF file 70K, Supplementary Figure 1. RET expression with Drug Treatment; Supplementary Figure 2. RET Protein Expression in a Subset of Primary Cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f189e077a8d01806aea4778252dbcf
https://doi.org/10.1158/1078-0432.22448339.v1
https://doi.org/10.1158/1078-0432.22448339.v1
Publikováno v:
J Am Coll Surg
INTRODUCTION: Breast angiosarcoma is a rare malignancy classically associated with hematogenous metastases. We sought to determine the prevalence of pathologic nodal involvement in patients with non-metastatic, resected breast angiosarcoma and its as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf1c19d0a11bb56dfcfdbd58f07f9caa
https://doi.org/10.1097/xcs.0000000000000131
https://doi.org/10.1097/xcs.0000000000000131